Skip to search formSkip to main contentSkip to account menu

Depostat

Known as: Primostat, Schering Brand of Gestonorone Caproate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The effect of Depostat has been evaluated by the aid of cystotono-sphincterotonometry in 30 subjects with prostatic adenoma of… 
Review
2000
Review
2000
Angiogenesis is known to be a critical process for the tumor growth and metastasis. There are many indigenous role-players in… 
1979
1979
Fifty‐four patients with advanced cystadenocarcinoma of the ovary were treated with gestronol (Depostat), 200 mg/week, by… 
1978
1978
Depostat treatment was found to reduce plasma testosterone and to have a gonadotrophin suppressive effect in males. In our study… 
1976
1976
One of the synthetic progestogenic compounds, Primostat,* has been proposed for the medical treatment of benign prostatic… 
1975
1975
The results of combined treatment with 90 mg estradiol valerianate and 300 mg 17-alpha-hydroxy-19-norprogesterone-capronate (SH… 
1973
1973
Benign prostatic hyperplasia is a major problem. Treatment should relieve symptoms and prevent progressive deterioration in upper… 
1973
1973
A clinical evaluation of nor progesterone caproate (Primostat) suggests that this drug has a limited place in the treatment of… 
1969
1969
The 4‐hr tissue Zn65 uptake, the prostatic, seminal vesicular, and testicular weight ratios, and the caudal prostatic…